Currently Enrolling Trials
Cabtreo is a combination of clindamycin phosphate (a lincosamide antibacterial), adapalene (a retinoid), and benzoyl peroxide.
Cabtreo is specifically indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.
Cabtreo is supplied as a topical ointment.
- Cleanse the affected area gently.
- After the skin is dry, apply a thin layer of Cabtreo to the affected area once daily. Wash hands thoroughly after application.
- Avoid the eyes, mouth, paranasal creases, mucous membranes, and areas of broken, eczematous, or sunburned skin.
Mechanism of Action
Clindamycin: Clindamycin is a lincosamide antibacterial.
Adapalene: Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown.
Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.
Adverse effects associated with the use of Cabtreo may include, but are not limited to, the following:
- application site reactions
Clinical Trial Results
The FDA approval of Cabtreo was based on two Phase 3 multicenter, randomized, placebo controlled clinical trials in 363 patients with acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count, and percentage of patients achieving treatment success (2 grade reduction of the EGSS (evaluators global severity score) from baseline with an EGSS score of clear (0) or almost clear (1)).